Analysis of FAERS data from 2004 to 2020 revealed significant associations between GLP-1 RA and various neoplasms, notably medullary thyroid cancer (PRR, 27.43), papillary thyroid cancer (PRR, 8.68), malignant pancreatic neoplasms (PRR, 9.86), and pancreatic neuroendocrine neoplasms (PRR, 2.86) [52]
These adverse effectsincluding nausea, vomiting, diarrhoea, constipation, and abdominal discomfortare dose-dependent and represent the most frequent reason for treatment discontinuation
Emerging evidence positions GLP-1RAs as a transformative candidate for ocular therapeutics
It can be used on its own or alongside professional treatments, he added
Clinical Trial Results STEP trials (Semaglutide Treatment Effect in People with obesity): Average weight loss of ~15% of total body weight
Consequently, Bbs5 / mice treated with semaglutide exhibited rapid weight loss (Figure 5E) and maintained a significant reduction in body weight, exceeding 10% compared with pretreatment levels (Figure 5F)
